Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.

AIDS (London, England) - 5 Nov 2004

Gianotti Nicola, Seminari Elena, Fusetti Giuliana, Salpietro Stefania, Boeri Enzo, Galli Andrea, Lazzarin Adriano, Clementi Massimo, Castagna Antonella

Abstract excerpt

Data from 20 highly drug-experienced HIV-infected patients receiving tenofovir plus didanosine as part of a salvage regimen were analysed. At baseline, all but one patient harboured a virus bearing at least one nucleoside excision mutation (NEM); in 13 cases (65%) three or more NEM were detectabl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Genetic

Share to Didanosine

Share to Drug Resistance, Multiple, Viral

Share to Organophosphonates

Share to Tenofovir

Source

Identifiers

PMID: 15577657
DOI: 10.1097/00002030-200411050-00016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15577657-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.PMID 15577657Read ↗

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.Semantic proximity Read ↗

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.Semantic proximity Read ↗

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.Semantic proximity Read ↗

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.Semantic proximity Read ↗

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.Semantic proximity Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.Semantic proximity Read ↗

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.Semantic proximity Read ↗

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.Semantic proximity Read ↗

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.Semantic proximity Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.